Annual CFO
-$24.13 M
-$381.20 K-1.61%
01 July 2024
Summary:
BriaCell Therapeutics annual cash flow from operations is currently -$24.13 million, with the most recent change of -$381.20 thousand (-1.61%) on 01 July 2024. During the last 3 years, it has fallen by -$16.38 million (-211.30%).BCTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$4.04 M
+$1.05 M+20.62%
01 July 2024
Summary:
BriaCell Therapeutics quarterly cash flow from operations is currently -$4.04 million, with the most recent change of +$1.05 million (+20.62%) on 01 July 2024. Over the past year, it has increased by +$3.57 million (+46.93%). BCTX quarterly CFO is now -6781.62% below its all-time high of $60.40 thousand, reached on 30 April 2020.BCTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$24.13 M
+$6.88 M+22.20%
01 July 2024
Summary:
BriaCell Therapeutics TTM cash flow from operations is currently -$24.13 million, with the most recent change of +$6.88 million (+22.20%) on 01 July 2024. Over the past year, it has increased by +$3.68 million (+13.24%). BCTX TTM CFO is now -91983.97% below its all-time high of -$26.20 thousand, reached on 31 October 2006.BCTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCTX Cash From Operations Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -1.6% | +46.9% | +13.2% |
3 y3 years | -211.3% | -126.9% | -154.7% |
5 y5 years | -481.7% | -402.8% | -526.0% |
BCTX Cash From Operations High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3 years | -211.3% | at low | -126.9% | +63.0% | -154.7% | +22.8% |
5 y | 5 years | -1805.8% | at low | -6781.6% | +63.0% | -4528.1% | +22.8% |
alltime | all time | <-9999.0% | at low | -6781.6% | +63.0% | <-9999.0% | +22.8% |
BriaCell Therapeutics Cash From Operations History
Date | Annual | Quarterly | TTM |
---|---|---|---|
July 2024 | -$24.13 M(+1.6%) | -$4.04 M(-20.6%) | -$24.13 M(-22.2%) |
Apr 2024 | - | -$5.08 M(-31.3%) | -$31.01 M(-0.8%) |
Jan 2024 | - | -$7.40 M(-2.7%) | -$31.26 M(+12.4%) |
Oct 2023 | - | -$7.61 M(-30.3%) | -$27.81 M(+17.1%) |
July 2023 | -$23.74 M(+90.2%) | -$10.92 M(+104.8%) | -$23.74 M(+47.0%) |
Apr 2023 | - | -$5.33 M(+34.9%) | -$16.15 M(+3.2%) |
Jan 2023 | - | -$3.95 M(+11.6%) | -$15.64 M(+9.8%) |
Oct 2022 | - | -$3.54 M(+6.5%) | -$14.25 M(+14.1%) |
July 2022 | -$12.48 M(+61.1%) | -$3.33 M(-31.1%) | -$12.48 M(+12.4%) |
Apr 2022 | - | -$4.82 M(+88.7%) | -$11.10 M(-6.4%) |
Jan 2022 | - | -$2.56 M(+43.7%) | -$11.87 M(+25.3%) |
Oct 2021 | - | -$1.78 M(-8.6%) | -$9.47 M(+22.2%) |
July 2021 | -$7.75 M(+512.2%) | -$1.95 M(-65.2%) | -$7.75 M(+25.0%) |
Apr 2021 | - | -$5.59 M(+3432.2%) | -$6.20 M(+1019.4%) |
Jan 2021 | - | -$158.20 K(+172.3%) | -$554.10 K(+6.3%) |
Oct 2020 | - | -$58.10 K(-85.4%) | -$521.30 K(-58.8%) |
July 2020 | -$1.27 M(-69.5%) | -$398.20 K(-759.3%) | -$1.27 M(-28.6%) |
Apr 2020 | - | $60.40 K(-148.2%) | -$1.77 M(-49.4%) |
Jan 2020 | - | -$125.40 K(-84.4%) | -$3.51 M(-9.0%) |
Oct 2019 | - | -$802.70 K(-11.4%) | -$3.85 M(-7.1%) |
July 2019 | -$4.15 M(+9.0%) | -$906.10 K(-45.8%) | -$4.15 M(-1.2%) |
Apr 2019 | - | -$1.67 M(+254.1%) | -$4.20 M(+19.2%) |
Jan 2019 | - | -$472.40 K(-56.9%) | -$3.52 M(-8.9%) |
Oct 2018 | - | -$1.10 M(+14.4%) | -$3.87 M(+1.6%) |
July 2018 | -$3.81 M(+147.9%) | -$958.00 K(-3.8%) | -$3.81 M(+25.2%) |
Apr 2018 | - | -$996.10 K(+22.0%) | -$3.04 M(+10.3%) |
Jan 2018 | - | -$816.70 K(-21.1%) | -$2.76 M(+22.7%) |
Oct 2017 | - | -$1.03 M(+435.9%) | -$2.25 M(+46.4%) |
July 2017 | -$1.54 M(+28.0%) | -$193.10 K(-72.9%) | -$1.54 M(-6.0%) |
Apr 2017 | - | -$713.00 K(+132.3%) | -$1.63 M(+28.6%) |
Jan 2017 | - | -$306.90 K(-4.8%) | -$1.27 M(+4.1%) |
Oct 2016 | - | -$322.30 K(+10.8%) | -$1.22 M(+1.7%) |
July 2016 | -$1.20 M(+28.2%) | -$290.90 K(-16.7%) | -$1.20 M(+6.8%) |
Apr 2016 | - | -$349.40 K(+36.1%) | -$1.12 M(+4.4%) |
Jan 2016 | - | -$256.80 K(-15.0%) | -$1.08 M(-12.7%) |
Oct 2015 | - | -$302.00 K(+40.5%) | -$1.23 M(+31.7%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
July 2015 | -$935.30 K(+157.0%) | -$214.90 K(-28.8%) | -$935.20 K(+9.8%) |
Apr 2015 | - | -$301.70 K(-27.0%) | -$851.40 K(+30.5%) |
Jan 2015 | - | -$413.10 K(+7410.9%) | -$652.20 K(+118.1%) |
Oct 2014 | - | -$5500.00(-95.8%) | -$299.00 K(-17.8%) |
July 2014 | -$364.00 K(-1.2%) | -$131.10 K(+27.9%) | -$363.90 K(-11.3%) |
Apr 2014 | - | -$102.50 K(+71.1%) | -$410.40 K(+2.1%) |
Jan 2014 | - | -$59.90 K(-14.9%) | -$402.10 K(+7.9%) |
Oct 2013 | - | -$70.40 K(-60.4%) | -$372.80 K(+1.2%) |
July 2013 | -$368.50 K(-3.4%) | -$177.60 K(+88.5%) | -$368.50 K(+25.3%) |
Apr 2013 | - | -$94.20 K(+207.8%) | -$294.00 K(-11.6%) |
Jan 2013 | - | -$30.60 K(-53.7%) | -$332.60 K(-16.4%) |
Oct 2012 | - | -$66.10 K(-35.9%) | -$398.00 K(+4.3%) |
July 2012 | -$381.50 K(-44.8%) | -$103.10 K(-22.4%) | -$381.60 K(-20.2%) |
Apr 2012 | - | -$132.80 K(+38.3%) | -$477.90 K(-20.4%) |
Jan 2012 | - | -$96.00 K(+93.2%) | -$600.30 K(-12.8%) |
Oct 2011 | - | -$49.70 K(-75.1%) | -$688.70 K(-0.3%) |
July 2011 | -$690.80 K(+123.3%) | -$199.40 K(-21.9%) | -$690.80 K(+34.8%) |
Apr 2011 | - | -$255.20 K(+38.4%) | -$512.40 K(+34.7%) |
Jan 2011 | - | -$184.40 K(+256.0%) | -$380.40 K(+40.7%) |
Oct 2010 | - | -$51.80 K(+146.7%) | -$270.40 K(-12.6%) |
July 2010 | -$309.40 K(+120.1%) | -$21.00 K(-83.0%) | -$309.40 K(-6.8%) |
Apr 2010 | - | -$123.20 K(+65.6%) | -$332.00 K(+63.1%) |
Jan 2010 | - | -$74.40 K(-18.1%) | -$203.60 K(+35.6%) |
Oct 2009 | - | -$90.80 K(+108.3%) | -$150.20 K(+6.9%) |
July 2009 | -$140.60 K(+60.9%) | -$43.60 K(-938.5%) | -$140.50 K(-1.4%) |
Apr 2009 | - | $5200.00(-124.8%) | -$142.50 K(-17.6%) |
Jan 2009 | - | -$21.00 K(-74.1%) | -$172.90 K(+6.8%) |
Oct 2008 | - | -$81.10 K(+77.9%) | -$161.90 K(+85.0%) |
July 2008 | -$87.40 K(-0.5%) | -$45.60 K(+81.0%) | -$87.50 K(+30.6%) |
Apr 2008 | - | -$25.20 K(+152.0%) | -$67.00 K(+18.4%) |
Jan 2008 | - | -$10.00 K(+49.3%) | -$56.60 K(-17.0%) |
Oct 2007 | - | -$6700.00(-73.3%) | -$68.20 K(-22.2%) |
July 2007 | -$87.80 K(<-9900.0%) | -$25.10 K(+69.6%) | -$87.70 K(+40.1%) |
Apr 2007 | - | -$14.80 K(-31.5%) | -$62.60 K(+31.0%) |
Jan 2007 | - | -$21.60 K(-17.6%) | -$47.80 K(+82.4%) |
Oct 2006 | - | -$26.20 K | -$26.20 K |
July 2006 | $0.00 | - | - |
FAQ
- What is BriaCell Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for BriaCell Therapeutics?
- What is BriaCell Therapeutics annual CFO year-on-year change?
- What is BriaCell Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for BriaCell Therapeutics?
- What is BriaCell Therapeutics quarterly CFO year-on-year change?
- What is BriaCell Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for BriaCell Therapeutics?
- What is BriaCell Therapeutics TTM CFO year-on-year change?
What is BriaCell Therapeutics annual cash flow from operations?
The current annual CFO of BCTX is -$24.13 M
What is the all time high annual CFO for BriaCell Therapeutics?
BriaCell Therapeutics all-time high annual cash flow from operations is $0.00
What is BriaCell Therapeutics annual CFO year-on-year change?
Over the past year, BCTX annual cash flow from operations has changed by -$381.20 K (-1.61%)
What is BriaCell Therapeutics quarterly cash flow from operations?
The current quarterly CFO of BCTX is -$4.04 M
What is the all time high quarterly CFO for BriaCell Therapeutics?
BriaCell Therapeutics all-time high quarterly cash flow from operations is $60.40 K
What is BriaCell Therapeutics quarterly CFO year-on-year change?
Over the past year, BCTX quarterly cash flow from operations has changed by +$3.57 M (+46.93%)
What is BriaCell Therapeutics TTM cash flow from operations?
The current TTM CFO of BCTX is -$24.13 M
What is the all time high TTM CFO for BriaCell Therapeutics?
BriaCell Therapeutics all-time high TTM cash flow from operations is -$26.20 K
What is BriaCell Therapeutics TTM CFO year-on-year change?
Over the past year, BCTX TTM cash flow from operations has changed by +$3.68 M (+13.24%)